Elanco Animal Health Incorporated Revenue Growth Rates (ELAN), Current and Historic Growth - CSIMarket
CSIMarket
 


Elanco Animal Health Incorporated  (NYSE: ELAN)
 

ELAN's Revenue Growth by Quarter and Year

Elanco Animal Health Incorporated's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ELAN/growth
https://api.csimarket.com/api/v1/companies/ELAN/fundamentals
https://api.csimarket.com/api/v1/companies/ELAN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
ELAN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1,265.00
2nd Quarter June 1,368.00
1st Quarter March 1,371.00
FY 4,004.00

ELANs Annual Revenue
Elanco Animal Health Incorporated's Revenue in the fiscal year 2025 $ 4,715.00 millions
Elanco Animal Health Incorporated's Revenue in the fiscal year 2024 $ 4,439.00 millions
Elanco Animal Health Incorporated's Revenue in the fiscal year 2023 $ 4,417.00 millions
Elanco Animal Health Incorporated's Revenue in the fiscal year 2022 $ 4,411.00 millions
Elanco Animal Health Incorporated's Revenue in the fiscal year 2021 $ 4,765.00 millions




ELAN Revenue third quarter 2026 Y/Y Growth Comment
Elanco Animal Health Incorporated achieved in the third quarter 2026, above Company average Revenue increase of 11.26% year on year, to $ 1,265.00 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 103 other companies have achieved higher Revenue growth. While Elanco Animal Health Incorporated' s Revenue growth of 11.26% ranks overall at the positon no. 1743 in the third quarter 2026.




ELAN Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 11.26 %
2nd Quarter June 10.23 %
1st Quarter March 14.92 %
FY   -

Financial Statements
Elanco Animal Health Incorporated's third quarter 2026 Revenue $ 1,265.00 millions ELAN's Income Statement
Elanco Animal Health Incorporated's third quarter 2025 Revenue $ 1,137.00 millions Quarterly ELAN's Income Statement


ELAN Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -7.53 %
2nd Quarter June -0.22 %
1st Quarter March 19.84 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #104
Healthcare Sector #274
Overall #1743

Revenue Y/Y Growth Statistics
High Average Low
118.15 % 9.06 % -24.99 %
(Sep 30 2021)   (Jun 30 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #104
Healthcare Sector #274
Overall #1743
Revenue Y/Y Growth Statistics
High Average Low
118.15 % 9.06 % -24.99 %
(Sep 30 2021)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Elanco Animal Health Incorporated's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
51.73 % 2.61 % -16.43 %
(Sep 30 2020)  


ELAN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Elanco Animal Health Incorporated disclosed drop in Revenue from the second quarter by -7.53% to $ 1,265.00 millions, from $ 1,368.00 millions achived in the previous reporting period.

But that's not important problem, as Elanco Animal Health Incorporated's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Elanco Animal Health Incorporated's Revenue growth quarter on quarter, overall rank is 1826.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #241
Overall #1826
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #241
Overall #1826
Revenue Q/Q Growth Statistics
High Average Low
51.73 % 2.61 % -16.43 %
(Sep 30 2020)  


ELAN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Elanco Animal Health Incorporated disclosed drop in Revenue from the second quarter by -7.53% to $ 1,265.00 millions, from $ 1,368.00 millions achived in the previous reporting period.

But that's not important problem, as Elanco Animal Health Incorporated's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Elanco Animal Health Incorporated's Revenue growth quarter on quarter, overall rank is 1826.


Elanco Animal Health Incorporated's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 5,020.00
Y / Y Revenue Growth (TTM) 11.95 %
Year on Year Revenue Growth Overall Ranking # 2643
Seqeuential Revenue Change (TTM) 2.6 %
Seq. Revenue Growth (TTM) Overall Ranking # 2502


Cumulative Revenue growth Comment
Elanco Animal Health Incorporated saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 11.95% year on year, to $ 5,020 millions if the fiscal year would have ended in Jun 30 2026.
Elanco Animal Health Incorporated's trailing twelve months Revenue growth was higher than company's average 7.78% and higher than 10.53% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 2.6 % from $4893 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at7.78%.

In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2181 to 2643.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 120
Healthcare Sector # 379
Overall # 2643

Revenue TTM Y/Y Growth Statistics
High Average Low
64.07 %
7.78 %
-8.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 360
S&P 500 # 2502
Cumulative Revenue growth Comment
Elanco Animal Health Incorporated saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 11.95% year on year, to $ 5,020 millions if the fiscal year would have ended in Jun 30 2026.
Elanco Animal Health Incorporated's trailing twelve months Revenue growth was higher than company's average 7.78% and higher than 10.53% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 2.6 % from $4893 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at7.78%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 2.6 % increase from $4893 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2181 to 2643.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 120
Healthcare Sector # 379
Overall # 2643

Revenue TTM Y/Y Growth Statistics
High Average Low
64.07 %
7.78 %
-8.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 360
S&P 500 # 2502




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ELAN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions


About Elanco Animal Health Incorporated Revenue Growth Rates (ELAN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Elanco Animal Health Inc (CIK 1739104).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001739104-26-000057
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Elanco Animal Health Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.